Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Basin Energy LtdExpands REE and Uranium Footprint at...
Altech Batteries LtdBoard Renewal and Strategic Focus
Expands REE and Uranium Footprint at Sybella-Barkly
Altech – Board Renewal and Strategic Focus
Altris Engineering Appointed to Optimise & Lead Seymour...
Locksley Resources Limitedto Establish ADR Program with BNY...
Corazon Mining Limited (ASX: CZN) – Trading Halt
Massan Resource Infill and Extension Drilling Delivers More...
Crypto Market Update: CME Outage Halts Futures Trading...
Crypto Market Update: UK Backs “No Gain, No...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Business

DOJ sues Walgreens, alleging it ‘knowingly’ filled millions of invalid prescriptions

by admin January 20, 2025
January 20, 2025
DOJ sues Walgreens, alleging it ‘knowingly’ filled millions of invalid prescriptions

The Department of Justice said Friday that it sued pharmacy giant Walgreens over allegedly dispensing millions of unlawful prescriptions.

The DOJ said that Walgreens from August 2012 until the present “knowingly” filled those prescriptions, which “lacked a legitimate medical purpose, were not valid, and/or were not issued in the usual course of professional practice.” 

“This lawsuit seeks to hold Walgreens accountable for the many years that it failed to meet its obligations when dispensing dangerous opioids and other drugs,” said Principal Deputy Assistant Attorney General Brian Boynton, head of the DOJ’s Civil Division.

Boynton said that Walgreens pharmacists filled millions of prescriptions with “clear red flags that indicated the prescriptions were highly likely to be unlawful.”

The company “systematically pressured its pharmacists to fill prescriptions, including controlled substance prescriptions, without taking the time needed to confirm their validity,” Boynton said. “These practices allowed millions of opioid pills and other controlled substances to flow illegally out of Walgreens stores.”

Some Walgreens patients died of overdose deaths shortly after getting invalid prescriptions filled at Walgreens, the DOJ alleges.

The 300-page lawsuit was filed Thursday in U.S. District Court in Chicago.

Walgreens in a statement said, “We are asking the court to clarify the responsibilities of pharmacies and pharmacists and to protect against the government’s attempt to enforce arbitrary ‘rules’ that do not appear in any law or regulation and never went through any official rulemaking process.”

“We will not stand by and allow the government to put our pharmacists in a no-win situation, trying to comply with ‘rules’ that simply do not exist,” Walgreens said.

“Walgreens stands behind our pharmacists, dedicated healthcare professionals who live in the communities they serve, filling legitimate prescriptions for FDA-approved medications written by DEA-licensed prescribers in accordance with all applicable laws and regulations.”

The suit alleges that although Walgreens issued written policies that reflected its understanding of legal obligations, the company took other actions which it knew prevented its pharmacists from complying with them.

“Walgreens prioritized profits over safety and compliance by implementing policies and practices that required pharmacists to fill prescriptions quickly and left pharmacists without enough time or resources to exercise their corresponding responsibility,” the suit said.

“One such metric was ‘Verify By Promise Time’ (VBPT), which expected a pharmacist to fill a prescription within 15 minutes for a ‘waiter’ (a customer waiting in the pharmacy store for the prescription),” the suit alleges.

“Walgreens also tracked pharmacists that dispensed a low rate of controlled substances through its ‘Non-dispensing Pharmacist Report,’” the suit said.

“Walgreens created this metric in part because it believed pharmacists who refused to fill controlled-substance prescriptions compromised Walgreens’s customer service.”

This post appeared first on NBC NEWS

previous post
Tech 5: Trump to Prioritize Crypto, Biden Blocks AI Chip Exports
next post
S&P 500 climbed 0.3%, and Nasdaq-100 futures jumped 0.7%

You may also like

There’s been a ‘meaningful shift’ in CEO confidence...

January 16, 2025

Target says its holiday sales were better than...

January 17, 2025

Dollar Tree says it’s winning over higher-income shoppers...

March 28, 2025

White House accuses Powell of mismanaging Federal Reserve,...

July 11, 2025

Trump says it’s ‘highly unlikely’ he will fire...

July 18, 2025

Data center boom in world’s largest market isn’t...

May 3, 2025

JPMorgan begins suing customers who allegedly stole thousands...

October 30, 2024

All Quiksilver, Billabong and Volcom stores to close...

February 7, 2025

NTSB grills Boeing execs on safety culture and...

August 9, 2024

Art created autonomously by AI can’t be copyrighted,...

March 21, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Basin Energy LtdExpands REE and Uranium Footprint at Sybella-Barkly

      December 1, 2025
    • Altech Batteries LtdBoard Renewal and Strategic Focus

      December 1, 2025
    • Expands REE and Uranium Footprint at Sybella-Barkly

      December 1, 2025
    • Altech – Board Renewal and Strategic Focus

      December 1, 2025
    • Altris Engineering Appointed to Optimise & Lead Seymour DFS

      December 1, 2025
    Promotion Image

    banner ads

    Categories

    • Business (909)
    • Economy (829)
    • Investing (3,370)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved